Journal
PHARMACOLOGY & THERAPEUTICS
Volume 217, Issue -, Pages -Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.pharmthera.2020.107662
Keywords
Immune checkpoint inhibitor; Neutrophil; PMN-MDSC; TME
Categories
Funding
- National Cancer Institute
- National Institutes of Health (USA) [R01CA225191, R01CA188341, P50228944]
Ask authors/readers for more resources
Immune checkpoint inhibitor therapy activates tumor-killing T-cells by releasing the brake of anti-tumor immunity, but a majority of patients are refractory to the therapy. Recent studies suggest that high neutrophil content is associated with poor response rates, indicating that neutrophil antagonism may improve the efficacy of immune checkpoint inhibitor therapy.
Immune checkpoint inhibitor therapy activates tumor-killing T-cells by releasing the brake of anti-tumor immunity. It has been approved as firstor second-line therapy in many cancer types. Unfortunately, a majority of immune checkpoint inhibitor recipients are refractory to the therapy. Recent investigations of the peripheral blood and tumor microenvironment of cancer patients indicate that high neutrophil content is associated with poor response rates, suggesting an opportunity for synergistic therapy. In the current review, we discuss the mechanisms of neutrophil-mediated immunosuppression in cancer and recent findings suggesting that neutrophil antagonism will improve the efficacy of immune checkpoint inhibitor therapy. (C) 2020 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available